Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $963.1K in total
- 6
- 13F holdersQ2 2026, +4 vs. previous quarter
- 192
- 13F valueReported value at the end of Q2 2026
- $2.24B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding GLUE, Q2 2026
1 superinvestor reports holding Monte Rosa Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.2%
Monte Rosa Therapeutics, Inc.'s share of the portfolio
- Shares
- 297,600
- Value
- $7.20M
Latest insider trades
Open-market purchases and sales by Monte Rosa Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 17, 2026 (view filing)4:05 PM ET | Jul 16 | 1 day | Warmuth MarkusPresident & CEO | SSale | −9.50K | $23.18 | −$220.2K | −1.6%585.0K after | |
| Jul 16, 2026 (view filing)4:10 PM ET | Jul 15 | 1 day | Champoux JenniferChief Operating Officer | SSale | −4.35K | $23.38 | −$101.7K | −6.5%62.4K after | 10b5-1 |
| Jul 7, 2026 (view filing)4:41 PM ET | Jul 6 | 1 day | Townson SharonChief Scientific Officer | SSale | −6.00K | $23.31 | −$139.8K | −8.1%67.8K after | 2 lots10b5-1 |
| Jul 1, 2026 (view filing)4:57 PM ET | Jun 30 | 1 day | Janku FilipChief Medical Officer | SSale | −5.41K | $24.50 | −$132.5K | −8.2%60.6K after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Janku FilipChief Medical Officer | SSale | −6.00K | $22.95 | −$137.7K | −9.1%60.0K after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Manning Anthony M.Director | SSale | −10.0K | $23.11 | −$231.1K | −100.0%0 after | |
| Jun 25, 2026 (view filing) | Jun 23-24 | 2 days | Janku FilipChief Medical Officer | SSale | −41.8K | $21.08 | −$882.1K | −41.1%60.0K after | 2 lots10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Townson SharonChief Scientific Officer | SSale | −3.00K | $20.00 | −$60.0K | −4.2%67.8K after | 10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Champoux JenniferChief Operating Officer | SSale | −2.17K | $20.00 | −$43.5K | −3.4%62.4K after | 10b5-1 |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Champoux JenniferChief Operating Officer | SSale | −2.18K | $19.00 | −$41.3K | −3.4%62.4K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Monte Rosa Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 8,861,171 | $214.4M | 0.02% | +2,140,983+31.9% | Added |
| NEA Management Company, LLC | 7,692,298 | $186.2M | 11.72% | 00.0% | Unchanged |
| BlackRock, Inc. | 6,843,087 | $165.6M | 0.00% | +1,205,403+21.4% | Added |
| TCG Crossover Management, LLC | 4,622,151 | $111.9M | 2.69% | 00.0% | Unchanged |
| Vestal Point Capital, LP | 4,600,000 | $111.3M | 2.60% | +996,535+27.7% | Added |
| BVF Inc | 4,460,886 | $108.0M | 2.76% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 4,345,736 | $105.2M | 0.53% | 00.0% | Unchanged |
| State Street Corp | 3,731,416 | $90.3M | 0.00% | +377,436+11.3% | Added |
| Suvretta Capital Management, LLC | 3,549,539 | $85.9M | 1.81% | −677,270−16.0% | Reduced |
| Vanguard Capital Management LLC | 3,412,927 | $82.6M | 0.00% | +312,682+10.1% | Added |